Next 10 |
2024-05-31 10:43:44 ET More on ATAI, COMPASS Pathways, etc. ATAI: Enormous Potential Upside But No Clarity Yet Psychedelics Closer To Commercialization; Compass Far And Away The Leader COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript Mind Medicine...
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, ann...
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
SciSparc Ltd. (SPRC) is expected to report for quarter end 2023-12-31
2024-04-16 08:28:48 ET More on pre-market losers & stocks. Financial information for Houston American Energy Financial information for Indonesia Energy Financial information for Organovo Holdings Compare metrics for HUSA to INDO, ONVO Read the f...
2024-04-12 08:32:45 ET More on Pre-market losers & stocks. Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment Adial stock rallies 81% on data for alcohol abuse drug Seeking Alpha’s Quant Rating on Adial Pharmaceuti...
2024-04-11 08:34:06 ET More on SciSparc Ltd. SciSparc gains on grant of patent for core technology in multiple jurisdictions in Europe SciSparc gains as Clearmind partnership yields 3 new international patent applications Financial information for SciSparc Ltd. ...
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signe...
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part ...
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the develo...
News, Short Squeeze, Breakout and More Instantly...
SciSparc Ltd. Company Name:
SPRC Stock Symbol:
NASDAQ Market:
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, ann...
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
SciSparc Ltd. (SPRC) is expected to report for quarter end 2023-12-31